Mucus hypersecretion in chronic obstructive pulmonary disease
- PMID: 11199104
- DOI: 10.1002/0470868678.ch5
Mucus hypersecretion in chronic obstructive pulmonary disease
Abstract
Most patients with chronic obstructive pulmonary disease (COPD) exhibit characteristics of airway mucus hypersecretion, namely sputum production, increased luminal mucus, submucosal gland hypertrophy and goblet cell hyperplasia. The clinical consequences of hypersecretion are impaired gas exchange and compromised mucociliary clearance, which encourages bacterial colonization and associated exacerbations. However, the extent of the contribution of mucus to pathophysiology of COPD is controversial. Early epidemiological studies found little evidence for the involvement of mucus in the age-related decline in lung function and mortality associated with COPD and concluded that chronic airflow obstruction and mucus hypersecretion were independent processes. Later studies found positive associations between phlegm production and decline in lung function, hospitalization and death. Thus, although not diagnostic for the condition, mucus hypersecretion contributes to morbidity and mortality in certain groups of patients with COPD. This suggests that it is important to develop drugs that inhibit mucus hypersecretion in these patients. Unfortunately, ambiguity in clinical studies of mucoactive drugs means that mucolytics are not recommended in clinical management. Future research should determine whether there is an intrinsic abnormality in mucus in COPD, which will determine development of appropriate inhibitors, which in turn can be used in 'proof of concept' and in treatment.
Similar articles
-
Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy.Monaldi Arch Chest Dis. 2000 Aug;55(4):324-32. Monaldi Arch Chest Dis. 2000. PMID: 11057087 Review.
-
New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways.J Aerosol Med Pulm Drug Deliv. 2010 Aug;23(4):219-31. doi: 10.1089/jamp.2009.0802. J Aerosol Med Pulm Drug Deliv. 2010. PMID: 20695774 Review.
-
Treatment of airway mucus hypersecretion.Ann Med. 2006;38(2):116-25. doi: 10.1080/07853890600585795. Ann Med. 2006. PMID: 16581697 Review.
-
Mucous hypersecretion and relationship to cough.Pulm Pharmacol Ther. 2013 Oct;26(5):510-3. doi: 10.1016/j.pupt.2013.02.003. Epub 2013 Feb 19. Pulm Pharmacol Ther. 2013. PMID: 23434445
-
Remodeling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 2):S76-80. doi: 10.1164/ajrccm.164.supplement_2.2106067. Am J Respir Crit Care Med. 2001. PMID: 11734472 Review.
Cited by
-
Glandular gene expression of sinus mucosa in chronic rhinosinusitis with and without cystic fibrosis.Am J Respir Cell Mol Biol. 2011 Sep;45(3):525-33. doi: 10.1165/rcmb.2010-0133OC. Epub 2010 Dec 22. Am J Respir Cell Mol Biol. 2011. PMID: 21177983 Free PMC article.
-
Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungs.Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16528-33. doi: 10.1073/pnas.1206552109. Epub 2012 Sep 24. Proc Natl Acad Sci U S A. 2012. PMID: 23012413 Free PMC article.
-
Analysis of airway secretions in a model of sulfur dioxide induced chronic obstructive pulmonary disease (COPD).J Occup Med Toxicol. 2006 Jun 7;1:12. doi: 10.1186/1745-6673-1-12. J Occup Med Toxicol. 2006. PMID: 16759388 Free PMC article.
-
Interleukin-Mediated Pendrin Transcriptional Regulation in Airway and Esophageal Epithelia.Int J Mol Sci. 2019 Feb 9;20(3):731. doi: 10.3390/ijms20030731. Int J Mol Sci. 2019. PMID: 30744098 Free PMC article. Review.
-
Lipopolysaccharides induce a RAGE-mediated sensitization of sensory neurons and fluid hypersecretion in the upper airways.Sci Rep. 2021 Apr 16;11(1):8336. doi: 10.1038/s41598-021-86069-6. Sci Rep. 2021. PMID: 33863932 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources